Skip to main contentAll experts

Bret Purcell

RES PROF

MD-MEDICINE

Orcid identifier0000-0003-2467-6622 (opens in a new tab)⁠
  • RES PROF
    MD-MEDICINE

GRANTS

  • GRANT
    Proof of Concept Post-exposure Prophylaxis (PEP) Efficacy with PK Endpoints in the Mouse Models of Inhalational Biothreat Agents
    Biomedical Advanced Research & Devlpmt Author30 May 2025 - 31 Mar 2027
    Active
  • GRANT
    Proof-of-Concept Treatment (Tx) Efficacy in the Mouse Models of Inhalational Biothreat Agents
    Biomedical Advanced Research & Devlpmt Author30 May 2025 - 31 Mar 2027
    Active
  • GRANT
    In vitro microbiological evaluation of Acurx DNA pol IIIC compounds against Category A Bacterial pathogens (B. anthracis)
    Acurx Pharmaceuticals13 Aug 2024 - 15 Sep 2024
    Expired
  • GRANT
    Batelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
    Defense Threat Reduction Agency18 Jul 2024 - 31 Dec 2024
    Expired
  • GRANT
    In Vitro Microbiological Evaluations of Delafloxacin Against Category A and B Bacterial Pathogen Panels
    Biomedical Advanced Research & Devlpmt Author17 Nov 2023 - 28 Mar 2024
    Expired
  • GRANT
    In vitro testing of 100 isolates of B. pseudomallei
    Biomedical Advanced Research & Devlpmt Author5 Sep 2023 - 31 Dec 2025
    Expired
  • GRANT
    Battelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
    Defense Threat Reduction Agency17 Oct 2022 - 31 Dec 2026
    Active
  • GRANT
    In Vitro Microbiological Evaluations of Antibody-Drug Conjugates (ADCs) Against Category A and B Bacterial Pathogen Panels
    National Institute of Health Niaid14 Apr 2022 - 31 Mar 2024
    Expired
  • GRANT
    Evaluation of Lefamulin dose to survival in mice following aerosol exposure to F. tularensis SchuS4
    Nabriva Therapeutics4 Mar 2022 - 30 Jun 2022
    Expired
  • GRANT
    In Vitro Microbiological Evaluations of Medinamycin (MedM), MsbA inhibitor P2129, MedM + SPR741, and MsbA inhibitor P2129 + SPR741 Against Category A and B Bacterial Pathogen Panels
    Prokaryotics11 Jan 2022 - 31 Mar 2022
    Expired
  • GRANT
    Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei
    Defense Threat Reduction Agency24 Mar 2021 - 1 Apr 2027
    Active
  • GRANT
    Teixobactin Development for Anthrax
    National Institute of Health Niaid22 Jan 2021 - 31 May 2021
    Expired
  • GRANT
    Project Bioshield
    1 Nov 2020 - 31 Dec 2021
    Expired
  • GRANT
    MICs for Wockhardt WCK-5222
    Wockhardt Bio Agriculture29 Oct 2020 - 26 Nov 2020
    Expired
  • GRANT
    SOW #1 - Paratek Subcontract- MICs
    Biomedical Advanced Research & Devlpmt Author21 Sep 2020 - 21 Nov 2020
    Expired
  • GRANT
    Battelle Subcontract 778380 SAB Year 1
    Defense Threat Reduction Agency15 May 2020 - 30 Sep 2024
    Expired